pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
CITY
Phase 1 · other · Cutaneous T-cell lymphomas (CTCL)
CITY for Cutaneous T-cell lymphomas (CTCL) is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP240605
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 1
- Modality
- other
- Indication
- Cutaneous T-cell lymphomas (CTCL)
- Status
- active
- Trials
- 1